Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Linch

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|November 25, 2010
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%Sajir G Mohamedbhai, Keith Sibson, Teresa Marafioti, et al.
Blood|July 9, 2008
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic diseaseAdam J Mead, Rosemary E Gale, Robert K Hills, et al.
British Journal of Haematology|April 20, 2012
Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myelomaLaura A Percy, Sally E Moore, Wendi Qian, et al.
British Journal of Haematology|April 21, 2018
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcomeRob S Sellar, Rosemary E Gale, Asim Khwaja, et al.
Blood|May 21, 2011
The prognostic significance of IDH2 mutations in AML depends on the location of the mutationClaire L Green, Catherine M Evans, Lu Zhao, et al.
Haematologica|October 14, 2017
Variable outcome and methylation status according to <i>CEBPA</i> mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatmentDima El-Sharkawi, Duncan Sproul, Christopher G Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemiaMarc R Mansour, Veronique Duke, Letizia Foroni, et al.
British Journal of Haematology|October 15, 2013
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphomaGraham P Collins, Anne N Parker, Christopher Pocock, et al.
British Journal of Haematology|January 5, 2020
In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutationCatherine Hockings, Satyen Gohil, Robin Dowse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2006
Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort StudyNadejda Y Mudie, Anthony J Swerdlow, Craig D Higgins, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|November 25, 2010
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%Sajir G Mohamedbhai, Keith Sibson, Teresa Marafioti, et al.
Blood|July 9, 2008
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic diseaseAdam J Mead, Rosemary E Gale, Robert K Hills, et al.
British Journal of Haematology|April 20, 2012
Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myelomaLaura A Percy, Sally E Moore, Wendi Qian, et al.
British Journal of Haematology|April 21, 2018
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcomeRob S Sellar, Rosemary E Gale, Asim Khwaja, et al.
Blood|May 21, 2011
The prognostic significance of IDH2 mutations in AML depends on the location of the mutationClaire L Green, Catherine M Evans, Lu Zhao, et al.
Haematologica|October 14, 2017
Variable outcome and methylation status according to <i>CEBPA</i> mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatmentDima El-Sharkawi, Duncan Sproul, Christopher G Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemiaMarc R Mansour, Veronique Duke, Letizia Foroni, et al.
British Journal of Haematology|October 15, 2013
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphomaGraham P Collins, Anne N Parker, Christopher Pocock, et al.
British Journal of Haematology|January 5, 2020
In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutationCatherine Hockings, Satyen Gohil, Robin Dowse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2006
Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort StudyNadejda Y Mudie, Anthony J Swerdlow, Craig D Higgins, et al.
Pageof 13